Article: article from journal or magazin.
Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction.
Publication types: Clinical Trial ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
BACKGROUND: Long-term use of cyclosporine (CsA) contributes to post-transplant cardiovascular disease (CVD). Hence, a reduction in CsA dosage in kidney transplant recipients (KTR) may improve long-term outcomes. We analyzed the effects of 50% CsA dose reduction on the CVD risk profile in stable KTR. METHOD: Thirty-one KTR on a regimen of CsA, prednisone and mycophenolate mofetil (MMF) were studied. Patients were randomized to either a) continue their previously determined CsA dose (control group, n = 15) or b) lower their CsA dose by 50% (CsA reduction group, n = 16). Renal function, blood pressure, lipid profile, plasma homocysteine (HCY), C-reactive protein (CRP), fibrinogen, and uric acid were compared at baseline and at 6 months. RESULTS: At 6 months, there was a significant improvement in allograft function, systolic blood pressure, number of anti-hypertensive medications and serum uric acid levels in the CsA reduction group. No significant decrease in plasma HCY, CRP, fibrinogen or improvement in lipid profile was found. In contrast, in the Control group, there was a significant increase in HCY, uric acid, and triglycerides. No acute rejection occurred in either group. CONCLUSIONS: A greater reduction in CsA dose could further improve CVD risk profiles, although this may increase the risk of acute or subclinical rejection.
Adult, Blood Pressure, C-Reactive Protein/analysis, Cardiovascular Diseases/epidemiology, Cyclosporine/administration & dosage, Cyclosporine/therapeutic use, Female, Graft Survival, Homocysteine/blood, Humans, Immunosuppressive Agents/administration & dosage, Immunosuppressive Agents/therapeutic use, Kidney Function Tests, Kidney Transplantation, Male, Mycophenolic Acid/analogs & derivatives, Mycophenolic Acid/therapeutic use, Postoperative Period, Prednisolone/therapeutic use, Prospective Studies, Risk Assessment, Risk Factors, Uric Acid/blood
Web of science
Last modification date